Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.54 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.50 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.49 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
| ▸ | HMGCR | P04035 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.46 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.46 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15186292 | 0.85 | HTR2A (0.53) | ACHESLC13A5ALOX5L3MBTL1GAA | |
| SCHEMBL1337566 | 0.84 | ACHE (0.54) | ACHEHMGCRALDH1A1CYP3A4L3MBTL1 | |
| SCHEMBL8282401 | 0.83 | ACHE (0.58) | ACHESLC13A5ALDH1A1CYP3A4TAAR1 | |
| SCHEMBL30546634 | 0.82 | TAAR1 (0.68) | ADRA1ATAAR1 | |
| SCHEMBL12476293 | 0.82 | SLC13A5 (0.52) | ACHESLC13A5ALDH1A1CYP3A4ADRA1A | |
| SCHEMBL8708761 | 0.82 | TAAR1 (0.68) | ADRA1ATAAR1 | |
| SCHEMBL11288361 | 0.81 | ACHE (0.60) | ACHESLC13A5ALDH1A1CYP3A4L3MBTL1 | |
| SCHEMBL24797465 | 0.80 | HTR2A (0.47) | ACHESLC13A5CYP3A4TSHR | |
| SCHEMBL12844526 | 0.80 | HMGCR (0.53) | GABRA1GABRB2ALOX5HMGCRADRA1A | |
| SCHEMBL5154843 | 0.80 | ADRA1A (0.70) | ADRA1ATAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12029739-B2 | SHP2 inhibitor and use thereof | KANAPH THERAPEUTICS INC. (KR) | 2024-07-09 | — | — | US | disclosed |
| US-9949966-B2 | Dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection | HOFFMAN-LA ROCHE INC. (US) | 2018-04-24 | — | — | US | disclosed |
| EP-2010576-B1 | BIS-ARYLARYLOXY CATALYTIC SYSTEM FOR PRODUCING ETHYLENE HOMOPOLYMERS OR ETHYLENE COPOLYMERS WITH ALPHA-OLEFINS | SK INNOVATION CO LTD (KR) | 2013-07-24 | — | — | EP | disclosed |
| US-7977477-B2 | Benzimidazole derivatives and their use as protein kinase inhibitors | ASTEX THERAPEUTICS, LIMITED (GB) | 2011-07-12 | — | — | US | disclosed |
| US-7902373-B2 | asthma; for treating prostaglandin D2 mediated diseases; e.g. 6-(3-fluorophenyl)-N-[1-(1-methyl-1H-tetrazol-5-yl)piperidin-4-yl]nicotinamide | PFIZER INC (US) | 2011-03-08 | — | — | US | disclosed |
| US-7645715-B2 | Bis-arylaryloxy catalytic system for producing ethylene homopolymers or ethylene copolymers with alpha-olefins | SK ENERGY CO., LTD. (KR) | 2010-01-12 | — | — | US | disclosed |
| EP-2010576-A1 | BIS-ARYLARYLOXY CATALYTIC SYSTEM FOR PRODUCING ETHYLENE HOMOPOLYMERS OR ETHYLENE COPOLYMERS WITH ALPHA-OLEFINS | SK Energy Co., Ltd. (KR) | 2009-01-07 | — | — | EP | disclosed |
| US-20080146569-A1 | Nicotinamide Derivatives | PFIZER INC. | 2008-06-19 | — | — | US | disclosed |
| WO-2007123362-A1 | BIS-ARYLARYLOXY CATALYTIC SYSTEM FOR PRODUCING ETHYLENE HOMOPOLYMERS OR ETHYLENE COPOLYMERS WITH ALPHA-OLEFINS | SK ENERGY CO., LTD. (KR) | 2007-11-01 | — | — | WO | disclosed |
| US-20070249490-A1 | BIS-ARYLARYLOXY CATALYTIC SYSTEM FOR PRODUCING ETHYLENE HOMOPOLYMERS OR ETHYLENE COPOLYMERS WITH ALPHA-OLEFINS | SK CORPORATION (KR) | 2007-10-25 | — | — | US | disclosed |
| US-20070135477-A1 | Benzimidazole derivatives and their use as protein kinases inhibitors | ASTEX THERAPEUCTICS, LIMITED (US) | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146569-A1 | Nicotinamide Derivatives | NNT, NAMPT, NADK | ACHE 1708/4885SLC13A5 216/4885GABRA1 2112/4885 |
| US-20070135477-A1 | Benzimidazole derivatives and their use as protein kinases inhibitors | CDK1, AURKA, CDK2 | ACHE 3364/4885SLC13A5 4718/4885GABRA1 2853/4885 |
| US-12029739-B2 | SHP2 inhibitor and use thereof | PTPN1, PTPN5, PTPN2 | ACHE 4486/4885SLC13A5 3936/4885GABRA1 3503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.